Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.

Journal of neuro-oncology - 1 Dec 2019

Guyot Anne, Duchesne Mathilde, Robert Sandrine, Lia Anne-Sophie, Derouault Paco, Scaon Erwan, Lemnos Leslie, Salle Henri, Durand Karine, Labrousse François

Abstract excerpt

PURPOSE: Assessment of the risk of recurrence is essential to determine the therapeutic strategy of meningioma treatment. Many relapsing or aggressive meningiomas show elevated mitotic and/or Ki67 indices, reflecting cell cycle deregulation. As CDKN2A is a key tumor suppressor gene involved in cell cycle control, we investigated whether CDKN2A alterations may be involved in tumor recurrence. METHODS: We carried...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p16

Share to Meningeal Neoplasms

Share to Meningioma

Share to Mutation

Share to Neoplasm Recurrence, Local

Source

Identifiers

PMID: 31729637
DOI: 10.1007/s11060-019-03333-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.PMID 31729637Read ↗

Molecular Profiling of 22 Primary Atypical Meningiomas Shows the Prognostic Significance of 18q Heterozygous Loss and CDKN2A/B Homozygous Deletion on Recurrence-Free SurvivalSemantic proximity Read ↗

ARID1A mutation associated with recurrence and shorter progression-free survival in atypical meningiomas.Semantic proximity Read ↗

Comparative genomic analysis of driver mutations in matched primary and recurrent meningiomasSemantic proximity Read ↗

Risk Factors and Genomic Characteristics of Recurrent Meningiomas Identified Through Routine Clinical TestingSemantic proximity Read ↗

Genetic Alterations Associated With Progression and Recurrence in MeningiomasSemantic proximity Read ↗

Genomic landscape of meningiomas.Semantic proximity Read ↗

Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomasSemantic proximity Read ↗

Genomic markers of recurrence risk in atypical meningioma following gross total resectionSemantic proximity Read ↗

Multiomic and clinical analysis of multiply recurrent meningiomas reveals risk factors, underlying biology, and insights into evolutionSemantic proximity Read ↗

NF2 mutations are associated with resistance to radiation therapy for grade 2 and grade 3 recurrent meningiomas.Semantic proximity Read ↗

Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomasSemantic proximity Read ↗

Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.